A C Mackinnon
Overview
Explore the profile of A C Mackinnon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
681
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Slack R, Mills R, Mackinnon A
Int J Biochem Cell Biol
. 2020 Nov;
130:105881.
PMID: 33181315
Galectin-3 is a beta-galactoside-binding mammalian lectin and part of the 15 member galectin family that are evolutionarily highly conserved. It is the only chimeric protein with a C-terminal carbohydrate recognition...
2.
Murray I, Gonzalez Z, Baily J, Dobie R, Wallace R, Mackinnon A, et al.
Nat Commun
. 2017 Oct;
8(1):1118.
PMID: 29061963
Mesenchymal cells expressing platelet-derived growth factor receptor beta (PDGFRβ) are known to be important in fibrosis of organs such as the liver and kidney. Here we show that PDGFRβ cells...
3.
Moore J, Mackinnon A, Man T, Manning J, Forbes S, Simpson K
Aliment Pharmacol Ther
. 2016 Nov;
45(3):443-454.
PMID: 27896824
Background: Acute liver failure (ALF) is associated with significant morbidity and mortality. Studies have implicated the immune response, especially monocyte/macrophages as being important in dictating outcome. Aim: To investigate changes...
4.
Hodkinson P, Mackinnon A, Sethi T
Int J Radiat Biol
. 2007 Sep;
83(11-12):733-41.
PMID: 17852559
Purpose: Lung cancer is the leading cause of cancer deaths in the developed world. Small cell lung cancer (SCLC) has the worst prognosis due to the emergence of resistance to...
5.
Hodkinson P, Elliott T, Wong W, Rintoul R, Mackinnon A, Haslett C, et al.
Cell Death Differ
. 2006 Jan;
13(10):1776-88.
PMID: 16410797
The emergence of resistance to chemotherapy remains a principle problem in the treatment of small-cell lung cancer (SCLC). We demonstrate that extracellular matrix (ECM) activates phosphatidyl inositol 3-kinase (PI3-kinase) signaling...
6.
Mackinnon A, Tufail-Hanif U, Lucas C, Jodrell D, Haslett C, Sethi T
Br J Cancer
. 2005 Feb;
92(3):522-31.
PMID: 15685238
Small-cell lung cancer (SCLC) is a particularly aggressive cancer, which metastasises early. Despite initial sensitivity to radio- and chemo-therapy, it invariably relapses, so that the 2-year survival remains less than...
7.
Waters C, Mackinnon A, Cummings J, Tufail-Hanif U, Jodrell D, Haslett C, et al.
Br J Cancer
. 2003 May;
88(11):1808-16.
PMID: 12771999
[Arg(6),D-Trp(7,9),N(me)Phe(8)]-substance P (6-11) (SP-G) is a novel anticancer agent that has recently completed phase I clinical trials. SP-G inhibits mitogenic neuropeptide signal transduction and small cell lung cancer (SCLC) cell...
8.
Mackinnon A, Waters C, Jodrell D, Haslett C, Sethi T
J Biol Chem
. 2001 Apr;
276(30):28083-91.
PMID: 11323408
Substance P analogues including [d-Arg1,d-Phe5,d-Trp7,9,Leu11]substance P (SpD) act as "broad spectrum neuropeptide antagonists" and are potential anticancer agents that inhibit the growth of small cell lung cancer cells in vitro...
9.
Mackinnon A, Waters C, Rahman I, Harani N, Rintoul R, Haslett C, et al.
Br J Cancer
. 2000 Sep;
83(7):941-8.
PMID: 10970698
[Arg(6), D-Trp(7,9), N(me)Phe(8)]-substance P (6-11) (antagonist G) inhibits small cell lung cancer (SCLC) growth and is entering Phase II clinical investigation for the treatment of SCLC. As well as acting...
10.
Sethi T, Rintoul R, Moore S, Mackinnon A, Salter D, Choo C, et al.
Nat Med
. 1999 Jun;
5(6):662-8.
PMID: 10371505
Resistance to chemotherapy is a principal problem in the treatment of small cell lung cancer (SCLC). We show here that SCLC is surrounded by an extensive stroma of extracellular matrix...